Cleerly ISCHEMIA vs Zio XT ECG Monitoring System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Cleerly
VS
by iRhythm Technologies

AI Verdict

Cleerly ISCHEMIA and Zio XT ECG Monitoring System are adjacent tools in cardiology, both leveraging AI for heart health, but with distinct focuses. Cleerly ISCHEMIA uses CCTA scans to assess coronary artery ischemia, plaque characteristics, and stenosis severity, aiding in personalized diagnosis and treatment planning for heart disease. In contrast, the Zio XT system is a wearable ECG biosensor for continuous cardiac monitoring, primarily focused on detecting and diagnosing cardiac arrhythmias over an extended period.

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you need a non-invasive, detailed assessment of coronary artery disease, including plaque characterization, stenosis severity, and the likelihood of vessel-level ischemia, based on CCTA scans. This tool is ideal for physicians aiming to personalize diagnosis and treatment planning for heart disease patients through advanced AI-powered imaging analysis.

View Cleerly ISCHEMIA →

Choose Zio XT ECG Monitoring System if…

Choose Zio XT ECG Monitoring System if you require continuous, long-term (up to 14 days) ambulatory cardiac monitoring for arrhythmia detection in patients experiencing symptoms like palpitations, shortness of breath, or dizziness, or for those who may be asymptomatic. This wearable, water-resistant biosensor is well-suited for improving diagnostic yield and patient compliance in detecting intermittent cardiac arrhythmias.

View Zio XT ECG Monitoring System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Cleerly ISCHEMIA Zio XT ECG Monitoring System
Pricing Contact for details Contact for pricing
Deployment Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) Cloud-based (AWS EC2 platform), no on-premise hardware required.
BAA Available Unknown Yes AI-estimated
FDA Status 1 AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio XT ECG Monitoring System

Zio XT offers superior patient usability due to its wearable, wire-free design that allows for normal daily activities, including showering, and boasts high patient compliance. Cleerly ISCHEMIA, while providing comprehensive reports, is a web-based platform analyzing CCTA scans, which inherently involves a more involved clinical procedure for the patient.

Clinical Value

Tie

Both tools demonstrate significant clinical value within their respective domains. Cleerly ISCHEMIA provides non-invasive, vessel-level ischemia likelihood and plaque characterization from CCTA, validated in multiple trials to outperform or be equivalent to other noninvasive measures of ischemia. Zio XT offers continuous, long-term ECG monitoring with high diagnostic yield for arrhythmias, supported by studies showing improved diagnostic accuracy and reduced retesting compared to other ambulatory monitors.

Pricing & Value

Tie

Both tools require contacting the company for specific pricing, indicating a lack of upfront transparency. However, both have established CPT codes for reimbursement, suggesting recognized value within the healthcare system.

Enterprise Readiness

Cleerly ISCHEMIA

Cleerly ISCHEMIA is deployed as a web-based platform with data transfer via Cleerly Proxy (VPN or virtual appliance) and offers integration with PowerScribe via API, indicating a readiness for integration into existing radiology and cardiology workflows. Zio XT is cloud-based, but its primary interaction is through a physical device and a cloud platform for reporting, with less emphasis on direct EMR or PACS integration details in the provided information.

Innovation

Tie

Both tools represent significant innovation in cardiac care. Cleerly ISCHEMIA utilizes AI to derive fractional flow reserve (FFR) estimation and detailed plaque characterization from standard CCTA scans, offering a non-invasive approach to ischemia detection. Zio XT innovates with its wearable, long-term, lead-free ECG biosensor and proprietary AI algorithm for arrhythmia detection, enhancing patient comfort and data collection over traditional methods.

Support & Docs

Tie

Both companies indicate a commitment to support. Cleerly states they are 'committed to the success of our customers' and aim to solve challenges quickly. iRhythm provides a clinical reference manual and patient instructions, along with customer care contact information. Without more specific details on the breadth and depth of their support offerings (e.g., SLAs, training programs), it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Cleerly ISCHEMIA Zio XT ECG Monitoring System
Tool Name Cleerly ISCHEMIA Zio XT ECG Monitoring System
Company Cleerly iRhythm Technologies
Description FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. Wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis.
Key Features AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization (volume, type, location), Stenosis severity assessment, 3D digital models of coronary arteries, Comprehensive interactive web-based reports, Integration with PowerScribe via API Wearable single-lead ECG biosensor (Zio biosensor), Continuous ambulatory cardiac monitoring for up to 14 days, Water-resistant design for normal daily activities, including showering, No external leads or wires for enhanced patient comfort and reduced artifacts, Proprietary, FDA-cleared deep-learned AI algorithm for ECG data analysis, Cloud-based software platform (ZEUS) for data storage, analysis, and reporting, Patient-activated button for symptomatic event logging, High patient compliance (up to 99%) and satisfaction
Specialties Cardiology, Radiology Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and Zio XT ECG Monitoring System.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Cleerly ISCHEMIA integrates with PowerScribe via API and provides comprehensive interactive web-based reports. The tool is designed to simplify the process, requiring only an additional order for ischemia prediction after a standard CCTA scan. Zio XT offers EHR integration, including seamless and secure transmission of orders and results through Epic's Aura network, aiming to streamline workflows and reduce manual steps. The Zio XT is also designed for patient ease of use, potentially reducing staff burden related to device application and patient education.
Cleerly ISCHEMIA demonstrates high diagnostic accuracy for coronary artery ischemia, with AUC values of 0.80 in the CREDENCE validation cohort and 0.85 in the PACIFIC-1 cohort, outperforming FFRcT, MPI, and PET in studies. It also shows high diagnostic performance for moderate and severe stenosis, with per-patient AUCs of 0.88 for u226550% stenosis and 0.92 for u226570% stenosis. Zio XT provides similar diagnostic accuracy to Holter devices for cardiac arrhythmias and has been shown to improve diagnostic yield compared to Holter monitoring (ranging from 2.3% to 32.5% for Zio XT versus 0% to 2.1% for Holter). The Zio XT's AI algorithm, overseen by cardiac physiologists, produces reports with high clinician agreement (99.9%).
Cleerly offers comprehensive interactive web-based reports to aid physicians in diagnosis and treatment. Zio XT provides a clinician portal (ZioSuite) for interpreting reports and managing patients, along with a provider mobile app. iRhythm also has an experienced and dedicated EHR team to assist with the integration process and offers go-live support for Epic integrations.
For Cleerly ISCHEMIA, the time-to-value is related to its ability to provide comprehensive analysis of atherosclerosis, stenosis, and ischemia from a single non-invasive CCTA test, potentially guiding clinical decision-making for revascularization and medical therapy. Zio XT has been associated with a significantly shorter time to results compared to Holter monitors (median of 21 days vs. 46 days), leading to faster diagnoses. Studies also suggest Zio XT can reduce the need for repeat tests and outpatient appointments, thereby improving workflow efficiency and potentially reducing healthcare costs.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.